Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expanding the Scope of Precision Care for Patients With HR-Positive Breast Cancers: Things You Should Know
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: June 10, 2022 Expiration: June 9, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Lilly
Novartis Pharmaceuticals Corporation
Sanofi Genzyme
Komal Jhaveri, MD
Program Director
Erica Mayer, MD, MPH
Laura M. Spring, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan risk-adapted adjuvant treatment strategies for patients with early-stage HR-positive/HER2-negative breast cancer based on available evidence and use of risk assessment algorithms, cellular proliferation biomarkers, and multigene assays
  • Select individualized treatment for patients with HR-positive/HER2-negative metastatic breast cancer based on the available evidence, guidelines, tumor characteristics, patient preferences, and expert guidance
  • Apply appropriate strategies to increase medication adherence rates in breast cancer patients to improve outcomes and mitigate medication resistance

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Komal Jhaveri, MD

Assistant Professor of Medicine
Weill Cornell Medical College
Associate Attending Physician
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Komal Jhaveri, MD, FACP, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Biotheranostics, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech, Jounce Therapeutics, Lilly, Novartis, Pfizer, Seattle Genetics, SunPharma, and Taiho Oncology and funds for research support paid to her institution from ADC Therapeutics, AstraZeneca, Clovis Oncology, Debio, Genentech, Immunomedics/Gilead, Lilly, Merck/VelosBio, Novartis, Novita Pharmaceuticals, Pfizer, Puma, and Zymeworks.

Faculty

Erica Mayer, MD, MPH

Institute Physician
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Erica L. Mayer, MD, MPH, has disclosed that she has received consulting fees from AstraZeneca, Gilead, Lilly, and Novartis.
Laura M. Spring, MD

Assistant Professor of Medicine
Harvard Medical School
Attending Physician, Medical Oncology (Breast Program)
Massachusetts General Hospital
Boston, Massachusetts

Laura M. Spring, MD, has disclosed that she has received consultant/advisor fees from Novartis and Puma and funds for research support paid to her institution from Merck and Phillips.

Staff

Kelly Brandt, PharmD
Kelly G. Brandt, PharmD, BCOP, BCPS, has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD has no relevant conflicts of interest to report.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for medical oncologists, pathologists, and other healthcare professionals who care for patients with breast cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new and emerging therapies into individualized treatment plans for HR-positive/HER2-negative breast cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 10, 2022, through June 09, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Expanding the Scope of Precision Care for Patients With HR-Positive Breast Cancers: Things You Should Know
  • CME

Loading...
In this on-demand webcast from a live symposium, experts Komal Jhaveri, MD, FACP; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, discuss how they apply current clinical evidence to develop personalized treatment plans for HR-positive/HER2-negative early and advanced breast cancer, including the use of current and emerging targeted therapies and strategies to promote patient adherence.
Komal Jhaveri, MD
Program Director
Erica Mayer, MD, MPH
Laura M. Spring, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: June 10, 2022 Expiration: June 9, 2023

Related Content

Expert faculty provide insights into the role and utility of Ki-67 testing in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

person default Sunil Badve, MD, FRCPath Laura M. Spring, MD Released: September 26, 2022

Dr Denise Yardley discusses key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 22, 2022 Expired: September 21, 2023

Downloadable slides from Dr Denise Yardley on key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Released: September 22, 2022

Slideset from Dr Denise Yardley on immunotherapy in early TNBC, from Clinical Care Options (CCO)

Denise A. Yardley, MD
Program Director
Released: September 15, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Lilly
Novartis Pharmaceuticals Corporation
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings